Navigation Links
Telik Announces Third Quarter 2010 Financial Results
Date:11/3/2010

PALO ALTO, Calif., Nov. 3, 2010 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today reported a net loss of $4.7 million, or $0.09 per share, for the third quarter ended September 30, 2010, compared with a net loss of $6.1 million, or $0.11 per share, for the comparable period in 2009.

For the quarter ended September 30, 2010, total operating costs and expenses were $4.7 million, compared with $6.2 million in the 2009 third quarter.  Operating expenses in the 2010 third quarter included stock-based compensation expense of approximately $0.4 million.  Operating expenses were approximately 24% lower in the third quarter of 2010 compared with the same period in 2009, primarily due to lower headcount, reduced research and clinical trial expenses and lower stock compensation expense.

For the nine months ended September 30, 2010, Telik reported a net loss of $14.9 million, or $0.28 per share, compared with a net loss of $19.5 million, or $0.37 per share, for the same period in 2009.  Total operating expenses for the first nine months of 2010 were $15.1 million, compared with $20.2 million for the same period in 2009.  Operating expenses in the first nine months of 2010 included approximately $1.5 million in stock-based compensation expense.  The reduction in operating expenses of approximately 26% in the first nine months of 2010 compared with the same period in 2009 was primarily due to lower headcount, reduced research and clinical trial expenses, and lower stock-based compensation and corporate administrative expenses.

At September 30, 2010, Telik had $27.4 million in cash, cash equivalents and investments including restricted investments, compared to $40.4 million at December 31, 2009.

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer and inflammatory diseases.  The company's most advanced investigational drug candidates in clinical development are Telintra®, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and Telcyta®, a tumor-activated prodrug for the potential treatment of advanced ovarian cancer and non-small cell lung cancer.  Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.  Additional information is available at www.telik.com.

This press release contains "forward-looking" statements, including statements regarding the future development of Telintra and Telcyta.  These forward-looking statements are based upon Telik's current expectations.  There are important factors that could cause Telik's results to differ materially from those indicated by these forward-looking statements, including, among others, if we are unable to raise adequate funds in the future, we will not be able to continue to fund our operations, research programs, preclinical testing and clinical trials, if clinical trials of TELINTRA or TELCYTA are delayed or unsuccessful, Telik's business would suffer, if Telik's competitors develop and market products that are more effective than its product candidates, or obtain marketing approval before Telik does, Telik's commercial opportunity will be reduced or eliminated, and if Telik does not obtain regulatory approval to market products in the U.S. and foreign countries, Telik will not be permitted to commercialize these product candidates.  Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its annual report on Form 10-K for the year ended December 31, 2009 and subsequent quarterly reports of Form 10-Q.  Telik does not undertake any obligation to update forward-looking statements contained in this press release.

TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.Telik, Inc.Statements of Operations(In thousands, except per share amounts)(Unaudited)Three Months Ended Nine Months EndedSeptember 30,September 30,2010200920102009Operating costs and expenses:Research and development

$
2,569$
3,416$
8,202$
,428General and administrative

2,1012,7596,8568,845Restructuring costs

---951Total operating costs and expenses

4,6706,17515,05820,224Loss from operations

(4,670)(6,175)(15,058)(20,224)Interest and other income (expense), net

1768132731Net loss

$
(4,653)$
(6,107)$
(14,926)$
(19,493)Basic and diluted net loss per share

$
(0.09)$
(0.11)$
(0.28)$
(0.37)Weighted average shares used to calculate basic and diluted net loss per share

53,55353,38153,51453,351Selected Balance Sheet Data(In thousands)(Unaudited)September 30,December 31,20102009Cash, cash equivalents, investments and restricted investments

$
27,428$
40,400Total assets

29,47946,153Stockholders' equity

27,62240,934
'/>"/>

SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Telik Awarded $1.2 Million in Grants for Qualifying Therapeutic Development Projects
2. Telik Announces Publication of Review Focused on the Inhibition of the Enzyme GSTP1-1 as a Target for New Cancer Treatments
3. Telik Announces Publication of a Case Report of a Sustained Hematologic Response in Myelodysplastic Syndrome Following an Abbreviated Exposure to Oral Telintra(R) (Ezatiostat HCl)
4. Telik Announces Fourth Quarter and 2009 Year End Financial Results and 2010 Financial Guidance
5. Telik Announces Initiation of Phase 1 Clinical Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets in Combination With Lenalidomide (Revlimid(R)) in Patients With Myelodysplastic Syndrome (MDS)
6. Telik Announces Third Quarter 2009 Financial Results
7. Telik Announces Publication of Positive Phase 1-2a Results of a Multicenter Study of TELCYTA(R) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
8. Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome
9. Telik Announces Presentation at ASCO Annual Meeting
10. Teliks Proteasome Inhibitor Program Meets a Preclinical Development Milestone
11. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)...  South Korean-based healthcare product Development Company I.M. Lab ... Kickstarter. The device will educate the user about ,proper, ... efficiency compared to the dated and pricey CPR training ... of the compression for a more informed CPR training. ... raise $5,000. cprCUBE ...
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
(Date:9/27/2017)... 27, 2017  Commended for their devotion to personalized service, ... as number one in the South Florida Business Journal,s 50 ... 5000 yearly list, the national specialty pharmacy has found its ... will soon be honored by SFBJ as the 2017 ... Set to receive his award in October, Bardisa said ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... HMP ... the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare ... City on October 11, 2017. , The annual award competition recognizes editorial and design ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations ... literacy software tool, and the Cancer Patient Education Network (CPEN), an independent professional ... announce a new strategic alliance. , As CPEN’s strategic partner, HLI will ...
Breaking Medicine News(10 mins):